Mr. Hao has been with Health Guard since July 2012, serving as General Manager and Board Member prior to being promoted in 2016 to Chairman of the Board and CEO of the company. Over the years, Mr. Hao has led the restructuring of the company as a shareholding enterprise, the listing of the company on the NEEQ, and the conclusion of Series A/B/C/D funding rounds at premium prices. Previously, Mr. Hao cofounded Sirius Holding Group.
Mr. Hao received an EMBA from the Donlinks School of Economics and Management, University of Science and Technology Beijing.
Mr. Liu is a Cofounder of Health Guard, and was Vice General Manager since the inception of the company before getting promoted to General Manager in 2016. He has been leading the company’s relentless efforts to develop HPV vaccines and other innovative recombinant vaccines over the past decade. Mr. Liu is a recipient of Special Government Allowance sponsored by the State Council and a 2015 Innovation Project-Etown Outstanding Experts. He garnered a National Science & Technology Progress Award (Third Prize).
Dr. Zhang joined the company in 2014, and served as head of the Formulation Department prior to being promoted to Vice General Manager (R&D) in 2016.
Previously, Dr. Zhang served as an R&D director at AbMax Biotechnology. He was a research associate at Cancer Institute of Chinese Academy of Medical Sciences from 2011 to 2012, and a research associate at Institute of Zoology of Chinese Academy of Sciences from 2009 to 2011.
Dr. Zhang received his Ph.D. from Beijing Normal University in 2004 and completed his postdoctoral training at Vanderbilt University. He was a 2017 Innovation Project-Etown Outstanding Expert.
Mr. Shen started at the company in 2011 and was promoted to Vice General Manager (Quality) in April 2013. He is the Qualified Person for product quality at the company.
Mr. Shen had previously served in various executive roles across the industry, including as Vice General Manager（Manufacturing）and Vice General Manager (Quality), respectively, at Harbin Laiboten Pharmaceutical, Chief Engineer and Qualified Person at Heilongjiang Fuhe Huxing Pharmaceutical, and Manufacturing and Technical Director at Sunflower Pharmaceutical.
Mr. Shen received a master’s degree in polymer materials from Harbin University of Science and Technology.
Ms. Dong joined the company in 2015, and had served as Finance Director before she was promoted to CFO in 2021.
She was an audit manager at Beijing Tianniu Investment from 2012-2015. Prior to that, Ms. Dong served as a finance manager at Heihe Xinghe Electricity.
Ms. Dong was a Certified Public Accountant.
Mr. Yi has been with the company since 2014, serving as Secretary of the Board before being promoted to Vice General Manager in 2021. He will continue to serve as Secretary of the Board as well.
Mr. Yi was previously an engineering supervisor at Reward Group and deputy director at the Beijing office of Menglan Xinghe, respectively.
He obtained Secretary of the Board qualification certificates from Shenzhen Stock Exchange in August 2016 and the NEEQ in April 2017, respectively. Mr. Yi was named a top NEEQ Secretary of the Board in 2016 and 2021.
Ms. Zhang joined the company in 2011 and have held multiple roles, including QA Supervisor, Pilot Plant Supervisor, Head of Process Development Department and Assistant to the vice General Manager. In July 2020, Ms. Zhang was appointed Vice General Manger of Beijing Health Guard and Health Guard (Kunming) in charge of process development and procurement.
Prior to joining the company, Ms. Zhang had worked for Gooddoctor Pharmaceutical Group and Zhendong Pharmaceutical, respectively, serving a variety of manufacturing, production and quality roles.
Ms. Zhang received a master’s degree in bioengineering from Beijing Institute of Technology.